- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00585910
Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
November 8, 2012 updated by: Timothy Wilens, MD, Massachusetts General Hospital
Efficacy and Safety/Tolerability of OROS MPH (Concerta) Plus Atomoxetine (ATMX) in Children and Adolescents (Age 6-17) With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children and adolescents ages 6-17.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
94
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02138
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female outpatients from 6 to 17 years old.
- Subjects with a DSM-IV diagnosis of ADHD by clinical interview, confirmed by the KSADS-E ADHD module.
- Subject with DSM-IV diagnosis of ADHD without previous treatment.
- Subjects with DSM-IV diagnosis of ADHD with a clinical history of a partial response to ATMX or methylphenidate as monotherapy.
- In phase I, subjects with a CGI-Severity of at least moderate impairment related to their ADHD (CGI >4).
- In phase II, subjects receiving therapeutic doses of ATMX with at least minor improvement in their clinical picture due to the ATMX as determined operationally (CGI-Improvement score indicating at least minor improvement relative to off-drug baseline) will be included.
- In phase II, only subjects receiving ATMX that also have evidence of persistent symptoms of ADHD and impairment related to their ADHD (a CGI-Severity of > minor impairment OR ADHD RS >18; AND GAF score <65) will have Concerta added to their regimen.
- Subjects' parents must provide informed consent and subjects' assent.
Exclusion Criteria:
- Pregnant or nursing females or females not using proper contraception.
- Subjects with a medical condition or treatment that will either jeopardize subject safety or affect the scientific merit of the study.
- Subjects (or their families) who do not appear to be reliable reporters of their condition or who indicate they will not be able to meet the schedule of visits for the duration of the study.
- Subjects with Mental Retardation or Organic Brain Syndromes.
- Subjects who have a lifetime history of a psychotic or bipolar disorder.
- Subjects with recent or current (past 30 days) major depressive disorder or a clinically significant anxiety disorder that would potentially necessitate treatment during the trial. g. Subjects with recent evidence (past 30 days) of suicidality or homicidality will not be enrolled.
- Subjects with a recent history (e.g. three months) of a substance use disorder; or those with a positive urine for substances of abuse will not be enrolled. Subjects will be told that a positive urine for substances of abuse will be disclosed to their parents.
- Subjects taking stimulants or other psychotropics at the time of the evaluation. Subjects will not be discontinued from their current medication regimen (not including ATMX), unless authorized and supervised by their treating physician.
- Treatment of stimulants within one week of the evaluation; tricyclic antidepressants, bupropion, cholinesterase inhibitors, modafinil, clonidine/guanfacine, lithium/anticonvulsants for behavioral control, or serotonin reuptake inhibitors (except fluoxetine) for four weeks prior to entry are prohibited. Treatment with antipsychotics/neuroleptics and fluoxetine for 8 weeks prior to entry are prohibited.
- Subjects using any prescribed or over-the-counter concurrent treatment for ADHD.
- Subjects with a history of a lack of response to either ATMX or methylphenidate.
- Subjects with a history of a serious adverse event to either ATMX or methylphenidate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Total treatment period is 7 weeks.
Atomoxetine treatment will be initiated and maintained for 4 weeks.
If the subject is a partial responder to atomoxetine treatment, OROS methylphenidate will then be added to his or her treatment regimen for the final 3 weeks of the study.
|
Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine.
If tolerated, they must remain on this dose for at least two weeks.
OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS)
Time Frame: 7 weeks
|
The primary outcome was the ADHD rating scale.
Change scores for the ADHD Rating Scale (RS), from baseline to endpoint (week 7 or last observation carried forward), were analyzed with paired t-tests and nonparametric Wilcoxon sign-rank tests.
The best score is a score of 0 (no ADHD symptoms) and the worst score is the highest score possible (54).
|
7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impressions - Level of Severity (CGIs) for ADHD and Other Psychiatric Disorders
Time Frame: 7 weeks
|
Secondary analyses allowed us to evaluate the effects of treatment on additional measures of functioning (CGIs for ADHD and other psychiatric disorders).
The CGI-Severity scale is as follows: 0 = Not assessed, 1 = normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, 7 = Among the most extremely ill patients.
|
7 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Primary Completion (ACTUAL)
December 1, 2007
Study Completion (ACTUAL)
December 1, 2007
Study Registration Dates
First Submitted
December 21, 2007
First Submitted That Met QC Criteria
January 3, 2008
First Posted (ESTIMATE)
January 4, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
November 14, 2012
Last Update Submitted That Met QC Criteria
November 8, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Adrenergic Uptake Inhibitors
- Methylphenidate
- Atomoxetine Hydrochloride
Other Study ID Numbers
- 2003-P-002180
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
Okinawa Institute of Science and Technology Graduate...Japan society for the promotion of science; Miyazaki International CollegeRecruiting
-
King's College LondonSouth London and Maudsley NHS Foundation TrustNot yet recruiting
-
Universidad de GranadaNot yet recruiting
-
Izmir Katip Celebi UniversityDokuz Eylul UniversityNot yet recruiting
-
Seattle Children's HospitalNational Institute of Mental Health (NIMH); University of WashingtonRecruiting
-
University of California, DavisRecruiting
-
Chen LiRecruiting
-
Region SyddanmarkRecruiting
-
Hugo W. Moser Research Institute at Kennedy Krieger...Active, not recruiting
Clinical Trials on Atomoxetine and OROS Methylphenidate
-
University of CincinnatiNational Institute on Drug Abuse (NIDA); University of Colorado, DenverCompletedADHD | Substance AbuseUnited States
-
Massachusetts General HospitalOrtho-McNeil Janssen Scientific Affairs, LLCCompleted
-
Janssen-Cilag International NVCompletedAttention Deficit Disorder With HyperactivityFrance, Germany, Spain, Switzerland, Netherlands, Portugal, Norway
-
Janssen-Cilag International NVCompletedAttention Deficit/ Hyperactivity DisorderFrance, Belgium, Germany, Spain, Switzerland, Denmark, Finland, Netherlands, Norway, Sweden, United Kingdom
-
Children's Hospital Medical Center, CincinnatiNational Institute of Mental Health (NIMH)CompletedADHD - Combined Type | ADHD - Inattentive TypeUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAttention Deficit Hyperactivity DisorderUnited States
-
Boston Children's HospitalNational Institute of Mental Health (NIMH)CompletedEpilepsy | Attention Deficit Disorder With HyperactivityUnited States
-
Children's Hospital of PhiladelphiaOrtho-McNeil Janssen Scientific Affairs, LLCCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Janssen Korea, Ltd., KoreaCompletedAttention-deficit Hyperactivity DisorderKorea, Republic of
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Completed